Gastrointestinal Cancer News

Patients with lung or colorectal cancer and insufficient financial reserves appeared more likely to experience high symptom burden and to report worsened quality of life, according to study results published in Journal of Clinical Oncology.

Long-term use of low-dose aspirin significantly reduced risk for overall cancer, especially gastrointestinal tract cancers, according to the results of two prospective cohort studies.

Patients who underwent radiotherapy during treatment for prostate cancer demonstrated a greater risk for second malignancies than those who did not receive radiotherapy, according to results of a systematic review and meta-analysis.

Patients with neurofibromatosis type 1 appeared at an increased risk for cancer diagnosis and mortality, according to the results of a population study.

Researchers found a scoring system based on age, gender, family history and smoking, to be useful for identifying asymptomatic patients at high risk for colorectal cancer and advanced adenoma.

The addition of bevacizumab to pemetrexed and cisplatin conferred a small but statistically significant improvement in OS among patients with malignant pleural mesothelioma, according to the results of a phase 3 trial.

A large proportion of esophageal adenocarcinomas were diagnosed within 1 year after a negative index endoscopy in adults diagnosed with nondysplastic Barrett’s esophagus, or Barrett’s esophagus with low-grade dysplasia, according to results from a recent study.

The FDA today approved everolimus to treat adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced or metastatic.

The rapidly rising costs of cancer care in the United States has created a considerable financial burden for many patients and their families. long

The U.S. Preventive Services Task Force’s draft guidelines for colorectal cancer screening do not recommend Cologuard, having considered only annual noninvasive screening strategies. However, an analysis of the modeling data used by the task force, which considered annual screening is uncommon due to poor adherence, found Cologuard at 3-year intervals is at least as effective as fecal blood tests every 2 to 3 years.